P

Prestige Brands

Over-the-counter health and wellness products

Overview

Prestige Consumer Healthcare focuses on consumer health and wellness products sold worldwide. It develops and markets over-the-counter medicines and related wellness products that are designed for everyday health needs and easy use, with a broad, globally distributed portfolio. Unlike some peers that operate in niche markets or regional scopes, Prestige Consumer Healthcare emphasizes a global reach with widely available brands that address common health concerns. Its goal is to help people manage everyday health issues through accessible, affordable products and a consistent consumer-brand experience across markets.

Work here?Claim your company

About Prestige Brands

Simplify's Rating
Why Prestige Brands is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

HealthcareConsumer Goods

Company Size

201-500

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1996

Get referred to Prestige Brands

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • November 5, 2026 Q2 revenue rose 22.7% to $336.3 million.
  • Breathe Right and LaCorium added $65.1 million, while ecommerce and gastrointestinal sales grew.
  • Prestige still raised a strong fiscal 2027 revenue guide despite Clear Eyes disruption.

What critics are saying

  • July 29, 2026 Clear Eyes recall exposed sterile manufacturing failure at Pillar5.
  • Ninth Circuit upheld the 2026 Clear Eyes pricing verdict; Supreme Court appeal remains unresolved.
  • If Pillar5 quality issues persist into 2027, Clear Eyes supply and reputation suffer.

What makes Prestige Brands unique

  • Clear Eyes and Breathe Right anchor Prestige’s category-leading OTC brand portfolio.
  • Pillar5 acquisition on December 18, 2025 gives Prestige in-house sterile ophthalmic manufacturing.
  • Management targets about 10% annual revenue growth and $900 million free cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options
  • Paid Vacation
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Life Insurance
  • Health Savings Account/Flexible Spending Account
  • Tuition Reimbursement
  • Performance Bonus

Stock Price

Growth & Insights and Company News

6 month growth

2%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Nov 5th, 2026
Prestige Consumer Healthcare Q2 revenue jumps 22.7% to $336.3M, but cuts outlook on Clear Eyes supply

Prestige Consumer Healthcare reported second-quarter revenue of $336.3 million, up 22.7% from $274.1 million a year earlier. The Breathe Right portfolio and LaCorium acquisitions contributed $65.1 million; excluding that and currency effects, revenue fell 1.6%, partly due to a decline in Clear Eyes. Net income fell to $25.3 million, or $0.53 per diluted share, from $42.2 million. Adjusted diluted earnings per share rose to $1.13 from $1.07. The company cut its fiscal 2027 outlook to $1,280 million to $1,290 million in revenue and $4.48 to $4.55 in adjusted diluted earnings per share. It cited variable Clear Eyes production at its Pillar5 site, which will limit supply in the second half.

Columnist24
Sep 5th, 2026
Clear Eyes drops recall raises questions beyond a sterility gap.

Clear Eyes drops recall raises questions beyond a sterility gap. A Clear Eyes drops recall covering 39,060 bottles of Maximum Itchy Eye Relief has put the Food and Drug Administration (FDA) on alert over a sterility problem that, so far, has harmed nobody, but that sits awkwardly against the backdrop of its manufacturer's broader eye-care ambitions. Prestige Consumer Healthcare, a subsidiary of Prestige Brands Holdings and the parent of distributor Medtech Products Inc, initiated the voluntary recall on 29 July 2026. The FDA updated its classification to a Class II recall on 14 August 2026, according to Ophthalmology Times. A Class II designation means the FDA judges the product to pose a moderate risk: use of or exposure to it 'may cause temporary or medically reversible adverse health consequences,' with serious consequences considered remote. It is not the agency's most urgent category, and as of publication, no adverse events have been linked to this lot. What the Clear Eyes drops recall actually covers. The problem is not that contamination has been confirmed. Rather, the manufacturer cannot assure that the drops are free from bacteria or fungi. That distinction matters: an FDA enforcement report cites a 'lack of assurance of sterility,' not evidence of active contamination. It is a process and documentation failure, not a proven health event, yet. The recall covers 15ml bottles carrying lot code 2552A and an expiration date of 30 September 2027. The FDA assigned recall number D-0766-2026 to the action, and the product carries NDC 67172-999-01, according to Dolman Law's recall summary. Consumers who bought the product at Walmart, Target, Kroger, Giant Eagle, Meijer, Dollar General, Family Dollar, CVS, or Walgreens, Fox Business confirmed the two pharmacy chains were also stocking the line, should stop using the drops immediately and return them for a full refund. Anyone with concerns about effects from the product should consult a pharmacist or healthcare provider. Sterility standards and the Pillar5 acquisition. The timing of the recall is, at minimum, inconvenient for Prestige. StockTitan, citing a Prestige Consumer Healthcare Form 8-K, reports that a wholly owned indirect subsidiary of Prestige entered into a definitive share purchase agreement to acquire Pillar5 Pharma Inc., described as a leading sterile ophthalmic manufacturer and the current supplier of Clear Eyes products, from ANJAC SAS. The deal is subject to closing conditions and is intended to expand the company's eye-care production capacity. That context gives the recall a sharper edge. Prestige is in the process of buying the very facility that makes Clear Eyes, apparently to gain greater control over the supply chain. A sterility assurance failure in the interim period (before that control is formalised) is precisely the kind of quality-management gap the acquisition was presumably designed to close. My read is that this recall is not a crisis. No injuries, no confirmed contamination, a moderate FDA classification. But the juxtaposition of a sterility complaint against a backdrop of acquiring a sterile ophthalmic manufacturer raises a reasonable question: how long has the oversight gap existed, and did it contribute to the strategic decision to buy the supplier outright? How the Clear Eyes recall compares with past incidents. Eye drop recalls have occasionally carried far graver consequences. In 2023, the FDA recalled EzriCare Artificial Tears after they were linked to an outbreak of Pseudomonas aeruginosa, a drug-resistant bacterial contamination that resulted in one death, injuries to 68 people, and, in a small number of cases, surgical removal of the affected eye. That was a Class I situation with confirmed casualties. The Clear Eyes action sits well below that threshold. Class II, no reported adverse events, and a lot-specific scope of fewer than 40,000 units. If Prestige handles the return process cleanly and the Pillar5 acquisition proceeds on schedule, this episode will likely be a footnote. The acquisition closing date is the figure worth watching: until Prestige controls its own sterile manufacturing, it remains exposed to exactly this kind of supplier-side assurance failure. Frank Arnold is a business writer and entrepreneurship analyst with a focus on startups, innovation, and market disruption. With years of experience covering the business landscape, he specializes in identifying emerging trends, profiling growth companies, and analyzing what makes businesses succeed or fail. Frank's pragmatic approach cuts through hype to deliver honest assessments of business strategies, leadership decisions, and market opportunities. His work helps readers understand the real challenges and opportunities facing modern enterprises. In his downtime, Frank is an avid homebrewer and blues guitar player.

Yahoo Finance
Aug 6th, 2026
Prestige Consumer Healthcare beats Q1 expectations with $106.3M record cash flow

Prestige Consumer Healthcare exceeded expectations in Q1 fiscal 2027, with total sales rising 6.5% to approximately $266 million. The company delivered record quarterly adjusted free cash flow of $83.7 million. The firm completed two strategic acquisitions — Breathe Right and Lacorium Health — expected to add over 20% to annualised revenue. The Breathe Right portfolio, contributing approximately $200 million in annual revenue, was integrated within 60 days of closing. Management raised full-year fiscal 2027 adjusted diluted earnings per share guidance to $4.55–$4.65 and adjusted free cash flow guidance to $270 million or more. Strong consumption growth was seen in gastrointestinal and skincare categories, with robust double-digit growth in e-commerce. However, Clear Eyes sales disappointed due to ongoing supply constraints. The company anticipates modest organic revenue decline in Q2 due to retailer order timing that benefited Q1.

Yahoo Finance
Aug 6th, 2026
Prestige Consumer Healthcare Q1 revenue hits $265.7M, beating estimates by 6%

Prestige Consumer Healthcare reported revenue of $265.71 million for the quarter ended June 2026, a 6.5% year-over-year increase. The company posted earnings per share of $0.98, up from $0.95 in the same period last year. The revenue figure exceeded the Zacks Consensus Estimate of $250.25 million by 6.18%. EPS also surpassed expectations, beating the $0.89 consensus estimate by 10.11%. North American OTC Healthcare revenues reached $226.21 million, whilst International OTC Healthcare generated $39.5 million, both segments showing growth compared to analyst estimates. Shares of Prestige Consumer Healthcare have returned 9.7% over the past month, outperforming the S&P 500's 3.3% gain. The stock currently carries a Zacks Rank of 4, indicating potential near-term underperformance versus the broader market.

Associated Press
Aug 6th, 2026
Prestige Consumer Healthcare Q1 revenue up 6.5% to $266M, raises full-year outlook to $1.3B

Prestige Consumer Healthcare reported first quarter fiscal 2027 revenue of $265.7 million, up 6.5% year-over-year, with organic sales growth of 3.2%. Adjusted diluted earnings per share reached $0.98, compared to $0.95 in the prior year period. The company closed acquisitions of Breathe Right and LaCorium Health in June and July, respectively. Breathe Right contributed $5.9 million to quarterly revenue. First quarter adjusted free cash flow hit a record $83.7 million, up from $78.2 million the previous year. The company's net debt position stood at approximately $2 billion as of 30 June 2026. Prestige raised its full-year fiscal 2027 outlook to reflect the acquisitions, now expecting revenue of $1.29 billion to $1.315 billion and adjusted diluted EPS of $4.55 to $4.65.

Recently Posted Jobs

Sign up to get curated job recommendations

Prestige Brands is Hiring for 11 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs